FDA Grants Rolling Review and CNPV Designation to Compass Pathways for TRD Treatment

Compass Pathways has received a Rolling Review and a Conditional New Product Vouchers (CNPV) designation from the FDA for its treatment targeting Treatment-Resistant Depression (TRD).